Summary
JCR Pharmaceuticals Co., Ltd. (4552) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has JCR Pharmaceuticals Co., Ltd. ever had a stock split?
JCR Pharmaceuticals Co., Ltd. Profile
| Pharmaceuticals Industry | Healthcare Sector | Toru Ashida CEO | JPX Exchange | JP3701000006 ISIN |
| DE Country | 987 Employees | 29 Sep 2026 Last Dividend | 30 Sep 2020 Last Split | - IPO Date |
Overview
JCR Pharmaceuticals Co., Ltd. is a prominent entity in the pharmaceutical industry, focusing on the research, development, manufacturing, and distribution of pharmaceutical products, regenerative medicines, and drug substances. Founded in 1975 and headquartered in Ashiya, Japan, the company operates both domestically and internationally. It specializes in providing innovative therapeutic solutions across a range of medical conditions. Moreover, JCR Pharmaceuticals actively engages in collaborations and joint research projects to advance novel biologic therapies and gene therapy delivery technologies, specifically targeting Central Nervous System (CNS) diseases. Its commitment to enhancing healthcare and bringing new solutions to market demonstrates its pivotal role in pharmacy and medicine.
Products and Services
- GROWJECT: Engineered for individuals suffering from growth hormone deficiency and short stature, GROWJECT represents a therapeutic advancement providing integral treatment solutions in the realm of endocrinology.
- IZCARGO: Dedicated to addressing Mucopolysaccharidosis type II, IZCARGO is a specialty pharmaceutical product aimed at treating this rare and challenging genetic disorder, showcasing JCR Pharmaceuticals’ commitment to tackling rare diseases.
- Agalsidase Beta BS I.V. Infusion: This product offers a significant therapeutic avenue for patients with Fabry disease, a rare genetic disorder, emphasizing the company's focus on developing treatments for less common, but impactful, health conditions.
- TEMCELL HS Inj: As a treatment for acute graft-versus-host disease, TEMCELL HS Inj highlights the company’s contributions to the field of regenerative medicine and its efforts in providing solutions for complex post-transplant complications.
- Epoetin Alfa BS and Darbepoetin Alfa BS Injections: These products are designed for the treatment of renal anemia, expanding the company's portfolio into the realm of nephrology and showcasing its commitment to developing therapies for chronic conditions.
In addition to these pharmaceutical products, JCR Pharmaceuticals also engages in the sale, import, and export of medical devices and laboratory instruments. The company's distribution network for medical and research equipment further underscores its holistic approach to addressing healthcare needs, from therapeutic solutions to essential medical infrastructure.
